Abstract:Chemoresistance remains a formidable hurdle against cancer therapy. Seeking for novel therapy strategies is an urgent need for those who no longer benefit from chemotherapy. Chemoresistance is usually associated with the dysfunction of intrinsic apoptosis. Targeting extrinsic apoptosis via TRAIL signaling and the death receptors could be a potential solution to treat chemoresistant cancer. A highly biocompatible nano system for codelivery of the TRAIL DNA and the death receptor sensitizer monensin was developed, in which low-molecular-weight PEI (LMW-PEI) was crosslinked by the sulfhydryl cyclodextrin via disulfide bonds, and then bound with DNA, thus forming the bioreducible polyplex cores. In addition, the cyclodextrin also functioned as a carrier for the hydrophobic monensin via host-guest inclusion. Poly-γ-glutamic acid (γ-PGA) was used to modify the polyplex core via charge interaction. The γ-PGA corona can specifically bind with the tumor-associated gamma-glutamyl transpeptidase (GGT) overexpressed on the tumor cells, and achieve tumor-targeting delivery. Moreover, the tumor-homing peptide RGD-modified γ-PGA was also prepared as the surface coating materials for further improving gene delivery efficiency. This gene delivery system was characterized by the dual ligand-targeting, dual stimuli-responsive features. The ligands of RGD and γ-PGA can target the tumor-associated receptors (i.e., integrin and GGT). The conformation of γ-PGA is pH-sensitive, and the tumor acidic micro environments could trigger the detachment of surface-coating γ-PGA. The disulfide crosslinking LMW-PEI is redox-sensitive, and its fast disassembling in the tumor cells could favor the efficient gene delivery. The anti-tumor efficacy was demonstrated both in vitro and in vivo. Moreover, MYC-mediated synthetic lethality could be an important mechanism for overcoming the drug resistance. An important finding of our studies is the demonstration of the in vivo treatment efficacy of TRAIL/monensin, thus providing a potential novel therapeutic strategy for overcoming drug-resistant cancer.

Programmable Metal/Semiconductor Nanostructures for mRNA-Modulated Molecular Delivery.

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

Modular Construction of Multifunctional Bioresponsive Cell-Targeted Nanoparticles for Gene Delivery.

Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy

Supramolecular-mediated Dual-Functional DNA Nanocomposites for Programmable Cancer Therapy.

Inhibition of Multidrug Resistance of Cancer Cells by Co‐Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes

Nanocarriers with Multi-Locked DNA Valves Targeting Intracellular Tumor-Related Mrnas for Controlled Drug Release

Programmable Tetrahedral DNA‐RNA Nanocages Woven with Stimuli‐Responsive siRNA for Enhancing Therapeutic Efficacy of Multidrug‐Resistant Tumors

mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene therapy

Multifunctional Aptamer-Based Nanoparticles for Targeted Drug Delivery to Circumvent Cancer Resistance

Multifunctional Molecular Beacons-Modified Gold Nanoparticle As a Nanocarrier for Synergistic Inhibition and in Situ Imaging of Drug-Resistant-Related Mrnas in Living Cells

MicroRNA-Responsive DNA-Programmed Nanomedicine with Controllability of Cascaded Events for Cancer Therapy Enhancement

Endogenous Stimuli-Responsive Nucleus-Targeted Nanocarrier for Intracellular Mrna Imaging and Drug Delivery

Spatio-Temporal Controlled Gene-Chemo Drug Delivery in a DNA Nanocomplex to Overcome Multidrug Resistance of Cancer Cells

A Smart Nanoassembly for Multistage Targeted Drug Delivery and Magnetic Resonance Imaging

Triggered Amplification of Gene Theranostics with High Accuracy and Efficacy Using Metallo-Nanoassemblies

A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of Mrna to Tumors.

Structure-Switchable DNA Programmed Disassembly of Nanoparticles for Smart Size Tunability and Cancer-Specific Drug Release.

Combinational Application of Metal–organic Frameworks‐based Nanozyme and Nucleic Acid Delivery in Cancer Therapy

Targeting Death Receptors for Drug-Resistant Cancer Therapy: Codelivery of Ptrail and Monensin Using Dual-Targeting and Stimuli-Responsive Self-Assembling Nanocomposites